18-Methoxycoronaridine attenuates nicotine-induced dopamine release and nicotine preferences in rats

Glick, Stanley D., Maisonneuve, Isabelle M., Visker, Kathleen E., Fritz, K. A., Bandarage, Upul K., Kuehne, Martin E. · 1998 · Psychopharmacology

AI-extracted · unverified · confirm at source

THERAPEUTIC EXPANSION: 18-MC extends to nicotine addiction - attenuates nicotine-induced NAc dopamine release (19h pretreatment) and abolishes nicotine preference 24h+. Reduces nicotine without affecting water intake.

Dosing: 10–40 mg/kg ibogaine or 18-MC (rat i.p.) (intraperitoneal)